Larvol Delta - Apnimed-Announces-Positive-Phase-2-Data-Study-APC004-Demonstrating-Improvement-in-Measures-of-Obstructive-Sleep-Apnea-and-a-DoseResponse-with-AD109-an-Oral-Pharmacologic-Investigational-Treatment-for-the-Disease

aroxybutynin/atomoxetine (AD109) - Apnimed

https://www.businesswire.com/news/home/20211013005231/en/Apnimed-Announces-Positive-Phase-2-Data-Study-APC-004-Demonstrating-Improvement-in-Measures-of-Obstructive-Sleep-Apnea-and-a-Dose-Response-with-AD109-an-Oral-Pharmacologic-Investigational-Treatment-for-the-Disease

Oct 13, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next